Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exercise vs ACBT Adherence · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Need for extra antibiotics (days) · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Change in VO2 peak during maximal exercise · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Effects of high‐ vs low‐added sugar consumption Cardiovascular event · Adults without diabetes or CVD High versus low‐added sugar consumption for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Effects of high‐ vs low‐added sugar consumption All‐cause mortality · Adults without diabetes or CVD High versus low‐added sugar consumption for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Upper limb exercise training vs control (no intervention/usual care/isotonic exercise) Time to mature · CKD patients who underwent AVF creation Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access (2022) · Cochrane | no estimate extracted | NR | No studies |
Upper limb exercise training vs control (no intervention/usual care/isotonic exercise) Dialysis efficacy indicator · CKD patients who underwent AVF creation Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access (2022) · Cochrane | no estimate extracted | NR | No studies |
Upper limb exercise training vs control (no intervention/usual care/isotonic exercise) Vascular access function · CKD patients who underwent AVF creation Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access (2022) · Cochrane | no estimate extracted | NR | No studies |
Upper limb exercise training vs control (no intervention/usual care/isotonic exercise) Adverse events · CKD patients who underwent AVF creation Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Constipation at 3 to < 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Constipation at 3 to < 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase only) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Change in body weight (kg) at 3 to < 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Specimen · children with presumed pulmonary tuberculosis Index tests: Xpert Ultra Role: an initial test Threshold for index… Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Specimen · children with presumed pulmonary tuberculosis Index tests: Xpert Ultra Role: an initial test Threshold for index… Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children (2022) · Cochrane | no estimate extracted | NR | No studies |
Motion control vs neutral / cushioned running shoes Runner satisfaction with footwear · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Motion control vs neutral / cushioned running shoes Adverse events (e.g. skin complaints) other than musculoskeletal injuries · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Motion control vs neutral / cushioned running shoes Number of runners requiring hospital admission or surgery, or both, for musculoskeletal injury or adverse event · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Soft vs hard running shoes Number of lower‐limb running injuries · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Soft vs hard running shoes Number of runners who failed to return to running or their previous level of running · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Soft vs hard running shoes Runner satisfaction with footwear · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Soft vs hard running shoes Adverse events (e.g. skin complaints) other than musculoskeletal injuries · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Soft vs hard running shoes Number of runners requiring hospital admission or surgery, or both, for musculoskeletal injury or adverse event · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Neutral / cushioned vs minimalist running shoes Number of lower‐limb running injuries · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Running shoes recommended and selected on foot posture vs running shoes not recommended and selected on foot posture Number of runners sustaining a lower‐limb running injury · military personnel Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Running shoes recommended and selected on foot posture vs running shoes not recommended and selected on foot posture Number of runners who failed to return to running or their previous level of running · military personnel Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Running shoes recommended and selected on foot posture vs running shoes not recommended and selected on foot posture Runner satisfaction with footwear · military personnel Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Running shoes recommended and selected on foot posture vs running shoes not recommended and selected on foot posture Adverse events (e.g. skin complaints) other than musculoskeletal injuries · military personnel Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Running shoes recommended and selected on foot posture vs running shoes not recommended and selected on foot posture Number of runners requiring hospital admission or surgery, or both, for musculoskeletal injury or adverse event · military personnel Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Neutral / cushioned vs minimalist running shoes Number of runners who failed to return to running or their previous level of running · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Neutral / cushioned vs minimalist running shoes Adverse events (e.g. skin complaints) other than musculoskeletal injuries · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Neutral / cushioned vs minimalist running shoes Number of runners requiring hospital admission or surgery, or both, for musculoskeletal injury or adverse event · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Motion control vs neutral / cushioned running shoes Number of lower‐limb running injuries · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Motion control vs neutral / cushioned running shoes Number of runners who failed to return to running or their previous level of running · healthy adults participating in recreational running Running shoes for preventing lower limb running injuries in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
LHC + Dor vs LHC + angle of His accentuation Postoperative pathological acid reflux · adult patients (> 18 years) with achalasia Fundoplication in laparoscopic Heller's cardiomyotomy for achalasia (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | NR | No studies |
Berotralstat vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
C1 esterase inhibitor vs placebo or active control Disability (any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Plasma‐derived C1 esterase inhibitor vs placebo or active control Disability(any validated scale) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Nanofiltered C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Avoralstat vs placebo Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |